Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 50Lymphoid 50Dermatologic 36Myeloid 19Plasma cell 15Genitourinary 11Classical hematology 10Sarcoma 8Breast 7Gynecologic 6Gastrointestinal 5CNS 4Thoracic 2Head & Neck 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1

Interventions

Cisplatin 28Irinotecan 18Gemcitabine 18Paclitaxel 14alvocidib 13Fluorouracil 11Oxaliplatin 10Cyclophosphamide 10Carboplatin 10Leucovorin 8Bortezomib 8Biopsy 8Taxes 7Radiotherapy 7Pemetrexed 7Magnetic Resonance Spectroscopy 7Doxorubicin 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7Specimen Handling 6tanespimycin 5Vorinostat 5LMB-100 5Early Intervention, Educational 5Bevacizumab 5temsirolimus 4sargramostim 4Sorafenib 4Sirolimus 4Platinum 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × fludarabine phosphate × Other solid neoplasm × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡